Novoste first off the block to sell breakthrough radiation treatment for coronary arteries
This article was originally published in Clinica
Novoste has become the first company to commercialise intracoronary radiation technology, viewed by some as the next potential breakthrough technology for improving angioplasty outcomes after stents.
You may also be interested in...
Pfizer has now received a formal European Commission approval for its Nyvepria biosimilar pegfilgrastim. The approval puts the firm in direct competition with several other versions of the Neulasta original.
AstraZeneca's research head admits that the half dose approach was a lucky mistake - but one that could boost the vaccine's effectiveness and supplies. The US regulator may not be persuaded, however.
Alvotech has struck a major deal with Yangtze River Pharmaceutical that will allow eight of the biosimilars developer’s products to be commercialized in China.